AXA pharmaceutical announces the appointment of Jeff kmetz as chief business officer

On February 14, AXA pharmaceutical announced the appointment of Jeff kmetz as the company's chief business officer, reporting to the company's chairman, Dr Yang Dajun Mr kmetz will be fully responsible for the company's business operation and business development Mr kmetz has more than 25 years of experience in the global pharmaceutical and biotechnology industry Prior to joining AXA Pharma, he served as the chief business officer of pulse Biosciences; previously, he held senior management positions related to business operations in pharmaceuticals and alexion "We sincerely welcome Jeff to join the company's senior management team," said Dr Yang Dajun "He has made impressive achievements in formulating and implementing tumor focused product management strategies and business operations over the years We look forward to fully tap the unique advantages of AXA pharmaceutical in the apoptosis targeted product pipeline with Jeff's help, and lead the company into the commercialization process " Mr kmetz said: "I am very interested in the apoptotic targeting product pipeline of AXA As the company's chief business officer, I look forward to this role to give full play to my experience in blood / tumor, especially in business development strategy, and contribute to the company's future development " In his previous career, Mr Kmetz has been an executive in marketing and business development for many years Before joining AXA, he was the chief business officer of pulse Biosciences, responsible for the development of the company's nanopulse technology in the field of cancer Before that, Mr kmetz was responsible for the business development and marketing of pharmacyclics He led the formulation and implementation of the commercialization and life cycle management strategy of the BTK inhibitor imbruvica ® (irutini), and achieved great success The blockbuster product prompted the company to be acquired by abbvie for $21 billion in 2015 Previously, Mr kmetz worked in the blood tumor business departments of Bayer, alexion and other companies, responsible for the relevant marketing and marketing work Mr kmetz holds a bachelor's degree from Virginia Tech About Yasheng pharmaceutical, Yasheng pharmaceutical is an original new drug R & D enterprise based in China and facing the world It is committed to developing innovative drugs in the fields of cancer, hepatitis B and aging related diseases The company has a self-developed protein protein interaction target drug design platform Yasheng pharmaceutical R & D product pipeline mainly focuses on the inhibitors of key proteins of apoptosis pathway By inhibiting Bcl-2, IAP or MDM2-p53, it can restart the apoptosis process of tumor cells; the second and third generation inhibitors for kinase mutants in cancer treatment, etc Eight new drug projects of the company have entered the phase I-II clinical development stage in China, the United States and Australia.